This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by Pari Pharma GmbH
Information provided by (Responsible Party):
Pari Pharma GmbH Identifier:
First received: September 4, 2013
Last updated: April 10, 2017
Last verified: April 2017
The study should create data for the selection of a clinically relevant primary endpoint to assess the efficacy and safety of Buparid/PARI SINUS as compared to Budes Nasal Spray in the therapy of chronic rhinosinusitis (CRS) with polyposis nasi in adult patients. Ideally, the selected parameter should allow a correlation between an objective methodology and the clinical outcome of the study patients.

Condition Intervention Phase
Rhinosinusitis Chronic Polyposis Drug: Budesonide Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study to Investigate the Efficacy and Safety of Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis (CRS) With Polyposis Nasi in Adult Patients

Resource links provided by NLM:

Further study details as provided by Pari Pharma GmbH:

Primary Outcome Measures:
  • Change of inflammation of the nasal mucosa and paranasal sinus [ Time Frame: Change from Baseline at Week 8 ]

    Magnetic Resonance Imaging

    • Thickness of mucosa
    • Lund-Mackay-Score

Secondary Outcome Measures:
  • Safety assessment [ Time Frame: 26 weeks ]
    Treatment-emergent adverse events (AEs)

Other Outcome Measures:
  • Health-specific quality of life [ Time Frame: 26 weeks ]
    SNOT 22 (Sino-Nasal Outcome Test 22)

  • Nasal obstruction [ Time Frame: 8 weeks ]

  • Expansion of polyposis nasi [ Time Frame: Week 0 and Week 8 ]
    Endoscopy (classification according to Rasp et al. 2000)

Estimated Enrollment: 20
Study Start Date: April 2014
Estimated Study Completion Date: March 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Buparid; Treatment A
Buparid 1 mg budesonide/2 ml nebuliser solution
Drug: Budesonide
Active Comparator: Budes; Treatment B
Budes® Nasal Spray 50 µg budesonide/pump
Drug: Budesonide
Nasal spray


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient with confirmed diagnosis of chronic rhinosinusitis (CRS) with polyposis nasi grade I-III
  • Patient with a PNIF of > 7 l/min separated for left and right side of the nose
  • Patient's written informed consent
  • Male or female,>= 18 years of age
  • Patient is able to undergo nasal therapy without restrictions
  • Capable of understanding the purpose and risk of the clinical trial
  • Female patients with childbearing potential must have a negative urine pregnancy test prior to first IMP administration
  • Patient has completed correctly the diary during the Wash-in Phase

Exclusion Criteria:

  • Patients with cystic fibrosis
  • Patients with polyposis nasi grade IV
  • Patients with prior sinonasal surgery (exemption: polypectomy)
  • Patients with primary ciliaritis
  • Pregnant or breastfeeding women
  • Patients with suspected active upper airway infection
  • Receipt of an investigational drug as part of a clinical trial within 4 weeks prior to first administration of IMP
  • Drug or alcohol abuse
  • End-stage malignancies
  • Known hypersensitivity to Budesonide
  • Patients with oral steroid therapy within the last 4 weeks
  • Patients with frequent epistaxis (> 2 per month)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01946711

Contact: Stefanie Prante +49 89 742846 ext 830

University Goettingen Recruiting
Goettingen, Germany, 37075
Contact: Martin Canis, Prof    +49 551 3989 ext 71   
Principal Investigator: Martin Canis, Prof         
UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz Recruiting
Mainz, Germany, 55131
Contact: Sven Becker, MD    +49 (0) 6131 17 ext 2099   
Principal Investigator: Sven Becker, MD         
University LMU Munich Recruiting
Munich, Germany, 81377
Contact: Mareike Haack, MD    +49 89 7095 ext 0   
Principal Investigator: Mareike Haack, MD         
Sponsors and Collaborators
Pari Pharma GmbH
Principal Investigator: Sven Becker, MD Johannes Gutenberg University Mainz
  More Information

Responsible Party: Pari Pharma GmbH Identifier: NCT01946711     History of Changes
Other Study ID Numbers: 12082.101
Study First Received: September 4, 2013
Last Updated: April 10, 2017

Keywords provided by Pari Pharma GmbH:

Additional relevant MeSH terms:
Nasopharyngeal Neoplasms
Colorectal Neoplasms
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Nasopharyngeal Diseases
Pharyngeal Diseases
Stomatognathic Diseases
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs processed this record on September 21, 2017